Peptic Ulcerations Are Related to Systemic Rather Than Local Effects of Low-Dose Aspirin

Clinical Gastroenterology and Hepatology

Volumn 6, Issue 3, 2008, Pages 309-313

  van Oijen, Martijn G H ^a,b   Dieleman, Jeanne P ^b   Laheij, Robert J F ^a,b   Sturkenboom, Miriam C J M ^b   Jansen, Jan B M J ^a   Verheugt, Freek W A ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CARBASALATE CALCIUM; DIURETIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; STEROID;

AGED; ARTICLE; BIOEQUIVALENCE; CHRONOTHERAPY; CLINICAL EVALUATION; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DATA BASE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG SUBSTITUTION; DRUG USE; ENDOSCOPE; FEMALE; FOLLOW UP; HAZARD RATIO; HUMAN; INCIDENCE; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PEPTIC ULCER; POPULATION RESEARCH; PRIMARY MEDICAL CARE; PROPORTIONAL HAZARDS MODEL; RISK; STATISTICAL SIGNIFICANCE;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NETHERLANDS; PEPTIC ULCER; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; UREA;

EID: 39949085414     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2007.12.018     Document Type: Article

References (15)

1. Pearson T.A., Blair S.N., Daniels S.R., et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 106 (2002) 388-391
2. Verheugt F.W.A. Aspirin, the poor man's statin. Lancet 351 (1998) 227-228
3. Verheugt F.W.A. In search of a super-aspirin for the heart. Lancet 349 (1997) 1409-1410
4. Facts and figures 2005 (2006), Foundation for Pharmaceutical Statistics, The Netherlands
5. Garcia Rodriguez L.A., and Hernandez-Diaz S. Risk of uncomplicated peptic ulcer among users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Am J Epidemiol 159 (2004) 23-31
6. Derry S., and Loke Y.K. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ 321 (2000) 1183-1187
7. Cryer B., and Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 117 (1999) 17-25
8. Murray F.E., Hudson N., Atherton J.C., et al. Comparison of effects of effervescent calcium carbasalate and aspirin on gastroduodenal mucosal damage in human volunteers. Gut 38 (1996) 11-14
9. Vlug A.E., van der Lei J., Mosseveld B.M., et al. Post-marketing surveillance based on electronic patient records: the IPCI project. Methods Inf Med 38 (1999) 339-344
10. van der Lei J., Duisterhout J.S., Westerhof H.P., et al. The introduction of computer-based patient records in The Netherlands. Ann Intern Med 119 (1993) 1036-1041
11. Lamberts H., Wood M., and Hofmans-Okkes I.M. International primary care classifications: the effect of fifteen years of evolution. Fam Pract 9 (1992) 330-339
12. WHO Collaborating Centre for Drug Statistics Methodology. ATC index with DDDs (2002), WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway
13. Lanza F.L., Royer Jr. G.L., and Nelson R.S. Endoscopic evaluation of the effects of aspirin, buffered aspirin and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 303 (1980) 136-138
14. Kelly J.P., Kaufman D.W., Jurgelon J.M., et al. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 348 (1996) 1413-1416
15. Garcia Rodriguez L.A., Hernandez-Diaz S., and de Abajo F.L. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiological studies. Br J Clin Pharm 52 (2001) 563-571